ST104P, An Anti-Angiogenic Agent

Abstract

The present invention relates to a method of treating a subject suffering non-tumor condition or disease associated with angiogenesis which comprises administering the subject in need of the treatment with an effective angiogenesis inhibiting dose of a tetrameric cyclic compound of 4,5-dihydroxynaphthalene-2,7, disulfonic acid linked by methylene bridges in a pharmaceutical acceptable carrier.

1 . A method of treating a subject suffering non-tumor condition or disease associated with undesirable angiogenesis which comprises administering the subject in need of the treatment with an effective angiogenesis inhibiting dose of a tetrameric cyclic compound of 4,5-dihydroxynaphthalene-2,7, disulfonic acid linked by methylene bridges in a pharmaceutical acceptable carrier.  
     
     
         2 . The method of  claim 1  wherein the undesirable angiogenesis occurs in diabetic retinopathy.  
     
     
         3 . The method of  claim 1  wherein the undesirable angiogenesis occurs in sickle cell anemia.  
     
     
         4 . The method of  claim 1  wherein the undesirable angiogenesis occurs in vein occlusion.  
     
     
         5 . The method of  claim 1  wherein the undesirable angiogenesis occurs in artery occusion.  
     
     
         6 . The method of  claim 1  wherein the undesirable angiogenesis occurs in age-related macular degeneration.  
     
     
         7 . The method of  claim 1  wherein the undesirable angiogenesis occurs in atherosclerosis.  
     
     
         8 . The angiogenesis inhibitor of  claim 1  wherein said condition or disease is rheumatoid arthritis.  
     
     
         9 . The angiogenesis inhibitor of  claim 1  wherein said condition or disease is systemic lupus.  
     
     
         10 . The angiogenesis inhibitor of  claim 1  wherein said condition or disease is osteoarthritis.  
     
     
         11 . The method of  claim 1  wherein the pharmaceutical acceptable carrier is adapted for oral, sublingual, rectal, nasal, vaginal, transdermal, intrajoint, ophthalmic (intravitreal, intracameral), or parenteral administration.  
     
     
         12 . The method of  claim 1  wherein the pharmaceutical acceptable carrier is adapted in the form of a tablet, a capsule, a cachet, a solution, an emulsion, a depository, a patch or a powder.  
     
     
         13 . The method of  claim 1  wherein the subject is a human or an animal.